Matches in SemOpenAlex for { <https://semopenalex.org/work/W4235331036> ?p ?o ?g. }
Showing items 1 to 96 of
96
with 100 items per page.
- W4235331036 endingPage "279" @default.
- W4235331036 startingPage "279" @default.
- W4235331036 abstract "279 Background: While bacillus Calmette-Guérin (BCG) is the most effective intravesical treatment for reducing recurrence and progression for high-risk non-muscle invasive bladder cancer (NMIBC), many patients are either refractory to treatment or relapse. We assessed the efficacy and safety of rAd-IFNα/Syn 3 (Instiladrin, FKD Finland), a replication deficient recombinant adenovirus gene transfer vector, for patients with high-grade (HG) BCG refractory or relapsed NMIBC. Methods: In this open-label, US multicenter (n=13), parallel-arm Phase II study (NCT01687244), 43 patients with HG BCG refractory or relapsed NMIBC were randomized 1:1 to receive intravesical rAd-IFNα/Syn3 at 1x10 11 or 3x10 11 viral particles/mL. Patients responding at months 3, 6, and 9 were re-treated at months 4, 7, and 10. Most patients (n=21) had a primary tumor classification of carcinoma in situ (CIS); 9 had both CIS and Ta/T1 disease and 10 had Ta/T1 disease alone. The primary endpoint was 12-month HG recurrence-free survival (RFS). All patients receiving at least one dose were included in efficacy and safety analyses. Results: Forty patients received rAd-IFNα/Syn3 (1 x 10 11 vp/mL: n=21; 3 x 10 11 vp/mL: n=19) between November 2012 and April 2015. Fourteen patients (35.0%; 90% CI 22.6%, 49.2%) remained free of HG tumor recurrence 12 months after initial treatment. Comparable 12 month HG RFS was noted between dosage arms, as well as between patients with refractory and relapsed NMIBC. Interestingly, the 12 month HG recurrence-free survival for patients with Ta/T1-only disease was 50% (5/10). rAd-IFNα/Syn3 was well-tolerated, with no Grade 5 adverse events (AEs), one Grade 4 AE (COPD; unrelated to treatment), and no patient discontinuing treatment due to an adverse event. The most frequently reported AEs were micturition urgency (n=16), dysuria and pollakiuria (n=13 each), fatigue (n=9), and nocturia (n=10). Conclusions: rAd-IFNα/Syn3 was well tolerated and demonstrated promising efficacy for patients with HG NMIBC after BCG therapy who are unable or unwilling to undergo radical cystectomy. A phase III trial utilizing this novel agent is ongoing. Clinical trial information: 01687244." @default.
- W4235331036 created "2022-05-12" @default.
- W4235331036 creator A5001279486 @default.
- W4235331036 creator A5002737792 @default.
- W4235331036 creator A5006253852 @default.
- W4235331036 creator A5016811631 @default.
- W4235331036 creator A5024685539 @default.
- W4235331036 creator A5034005227 @default.
- W4235331036 creator A5041923034 @default.
- W4235331036 creator A5044200134 @default.
- W4235331036 creator A5046653328 @default.
- W4235331036 creator A5048604566 @default.
- W4235331036 creator A5050166344 @default.
- W4235331036 creator A5052467775 @default.
- W4235331036 creator A5061624473 @default.
- W4235331036 creator A5065641791 @default.
- W4235331036 creator A5071741514 @default.
- W4235331036 creator A5072272174 @default.
- W4235331036 creator A5077350606 @default.
- W4235331036 creator A5077644150 @default.
- W4235331036 creator A5083920381 @default.
- W4235331036 creator A5088518998 @default.
- W4235331036 date "2017-02-20" @default.
- W4235331036 modified "2023-10-01" @default.
- W4235331036 title "Intravesical rad-IFNα/Syn3 for patients with high-grade, bacillus Calmette-Guérin (BCG) refractory or relapsed non-muscle invasive bladder cancer: A phase II randomized study." @default.
- W4235331036 doi "https://doi.org/10.1200/jco.2017.35.6_suppl.279" @default.
- W4235331036 hasPublicationYear "2017" @default.
- W4235331036 type Work @default.
- W4235331036 citedByCount "2" @default.
- W4235331036 countsByYear W42353310362018 @default.
- W4235331036 countsByYear W42353310362022 @default.
- W4235331036 crossrefType "journal-article" @default.
- W4235331036 hasAuthorship W4235331036A5001279486 @default.
- W4235331036 hasAuthorship W4235331036A5002737792 @default.
- W4235331036 hasAuthorship W4235331036A5006253852 @default.
- W4235331036 hasAuthorship W4235331036A5016811631 @default.
- W4235331036 hasAuthorship W4235331036A5024685539 @default.
- W4235331036 hasAuthorship W4235331036A5034005227 @default.
- W4235331036 hasAuthorship W4235331036A5041923034 @default.
- W4235331036 hasAuthorship W4235331036A5044200134 @default.
- W4235331036 hasAuthorship W4235331036A5046653328 @default.
- W4235331036 hasAuthorship W4235331036A5048604566 @default.
- W4235331036 hasAuthorship W4235331036A5050166344 @default.
- W4235331036 hasAuthorship W4235331036A5052467775 @default.
- W4235331036 hasAuthorship W4235331036A5061624473 @default.
- W4235331036 hasAuthorship W4235331036A5065641791 @default.
- W4235331036 hasAuthorship W4235331036A5071741514 @default.
- W4235331036 hasAuthorship W4235331036A5072272174 @default.
- W4235331036 hasAuthorship W4235331036A5077350606 @default.
- W4235331036 hasAuthorship W4235331036A5077644150 @default.
- W4235331036 hasAuthorship W4235331036A5083920381 @default.
- W4235331036 hasAuthorship W4235331036A5088518998 @default.
- W4235331036 hasConcept C121332964 @default.
- W4235331036 hasConcept C121608353 @default.
- W4235331036 hasConcept C126322002 @default.
- W4235331036 hasConcept C126894567 @default.
- W4235331036 hasConcept C141071460 @default.
- W4235331036 hasConcept C142424586 @default.
- W4235331036 hasConcept C168563851 @default.
- W4235331036 hasConcept C203092338 @default.
- W4235331036 hasConcept C2780352672 @default.
- W4235331036 hasConcept C71924100 @default.
- W4235331036 hasConcept C87355193 @default.
- W4235331036 hasConcept C90924648 @default.
- W4235331036 hasConceptScore W4235331036C121332964 @default.
- W4235331036 hasConceptScore W4235331036C121608353 @default.
- W4235331036 hasConceptScore W4235331036C126322002 @default.
- W4235331036 hasConceptScore W4235331036C126894567 @default.
- W4235331036 hasConceptScore W4235331036C141071460 @default.
- W4235331036 hasConceptScore W4235331036C142424586 @default.
- W4235331036 hasConceptScore W4235331036C168563851 @default.
- W4235331036 hasConceptScore W4235331036C203092338 @default.
- W4235331036 hasConceptScore W4235331036C2780352672 @default.
- W4235331036 hasConceptScore W4235331036C71924100 @default.
- W4235331036 hasConceptScore W4235331036C87355193 @default.
- W4235331036 hasConceptScore W4235331036C90924648 @default.
- W4235331036 hasIssue "6_suppl" @default.
- W4235331036 hasLocation W42353310361 @default.
- W4235331036 hasOpenAccess W4235331036 @default.
- W4235331036 hasPrimaryLocation W42353310361 @default.
- W4235331036 hasRelatedWork W1000839 @default.
- W4235331036 hasRelatedWork W1008122 @default.
- W4235331036 hasRelatedWork W12229326 @default.
- W4235331036 hasRelatedWork W15992128 @default.
- W4235331036 hasRelatedWork W1618377 @default.
- W4235331036 hasRelatedWork W20525436 @default.
- W4235331036 hasRelatedWork W3462907 @default.
- W4235331036 hasRelatedWork W3468639 @default.
- W4235331036 hasRelatedWork W404457 @default.
- W4235331036 hasRelatedWork W5301835 @default.
- W4235331036 hasVolume "35" @default.
- W4235331036 isParatext "false" @default.
- W4235331036 isRetracted "false" @default.
- W4235331036 workType "article" @default.